Compassionate Use Re-Infusion of ATLCAR.CD30

Status No longer available

Clinical Trial Summary

This protocol for compassionate use combines 2 different ways of fighting disease: antibodies and T cells. Both antibodies and T cells have been used to treat patients with cancers, and both have shown promise, but neither alone has been sufficient to cure most patients. This protocol combines both T cells and antibodies to create a more effective treatment. The investigational treatment is called autologous T lymphocyte chimeric antigen receptor cells targeted against the CD30 antigen (ATLCAR.CD30) administration. Prior studies have shown that a new gene can be put into T cells and will increase their ability to recognize and kill cancer cells. The new gene that is put in the T cells in this study makes a piece of an antibody called anti-CD30. This antibody sticks to leukemia cells because they have a substance on the outside of the cells called CD30. For this protocol, the anti-CD30 antibody has been changed so that instead of floating free in the blood part of it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD30 chimeric (combination) receptor-activated T cells seem to kill some of the tumor, but they do not last very long in the body and so their chances of fighting the cancer are unknown. The primary purpose of this protocol is to treat a single patient with a second dose of ATLCAR.CD30 T cells.

Clinical Trial Description

Lymphodepleting Chemotherapy: The patient will receive a lymphodepleting regimen of bendamustine 70mg/m2/day over 3 consecutive days and fludarabine 30mg/m2/day over 2 consecutive days. Bendamustine and fludarabine will be administered concomitantly. Dose reduction of bendamustine may occur per treating physician discretion based on prior toxicities and the clinical status of the patient. Administration of ATLCAR.CD30 T cells: Post lymphodepletion, if the patient meets eligibility criteria for cellular therapy, then will receive ATLCAR.CD30 T cells within 2-14 days after completing the pre-conditioning chemotherapy regimen. We will administer ATLCAR.CD30 T cells post lymphodepletion at a dose of 2 x 10^8 cells/m2. Duration of Therapy: Therapy under this compassionate use protocol involves 1 infusion of ATLCAR.CD30 cells. Duration of Follow-up: The patient will be followed for up to 15 years for replication-competent retrovirus evaluation or until death, whichever occurs first. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03914885
Study type	Expanded Access
Source	UNC Lineberger Comprehensive Cancer Center
Contact
Status	No longer available
Phase

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04653649` - CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.	Phase 1/Phase 2
Recruiting	`NCT04636255` - Physical Capacity in Hodgkin Lymphoma Survivors	N/A
Not yet recruiting	`NCT06421987` - Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors
Recruiting	`NCT05597761` - Immunogenicity of COVID-19 Vaccination in Autologous HSCT or CAR-T Cells Recipients
Active, not recruiting	`NCT03535948` - Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy
Completed	`NCT03155425` - PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma	Phase 2
Recruiting	`NCT03260101` - Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study
Recruiting	`NCT04776265` - RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT
Recruiting	`NCT04378647` - BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant	Phase 2
Recruiting	`NCT04758650` - Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis	Phase 2
Recruiting	`NCT05137886` - PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma	Phase 2
Recruiting	`NCT05798897` - Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma	Phase 1
Completed	`NCT04292626` - Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose	Phase 1
Active, not recruiting	`NCT04268706` - Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)	Phase 2
Recruiting	`NCT04638790` - First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)	Phase 3
Completed	`NCT01578967` - Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.